Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.41 USD | +6.16% | +2.99% | +135.93% |
04-17 | Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer | CI |
03-28 | Sector Update: Health Care Stocks Advance Premarket Thursday | MT |
Evolution of the average Target Price on Stoke Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Stoke Therapeutics, Inc.
TD Cowen | |
Canaccord Genuity | |
Wedbush | |
Needham & Co. | |
JPMorgan Chase | |
Cantor Fitzgerald | |
BofA Securities | |
Credit Suisse | |
HC Wainwright | |
Jefferies & Co. | |
UBS |
EPS Revisions
- Stock Market
- Equities
- STOK Stock
- Consensus Stoke Therapeutics, Inc.